FDA clears Glucowatch for use in children:
This article was originally published in Clinica
The US FDA has given Cygnus clearance to expand the market for it Glucowatch G2 Biographer to include its use in Type I diabetic children and adolescents aged 7 to 17 years. The FDA's decision was based on a 66-patient study that showed the device to be safe and effective in this patient popoulation. More than 150,000 children in the US suffer from diabetes, notes Cygnus, which says that its wristwatch-like Glucowatch monitor can provide up to six painless glucose measurements per hour for 13 hours. The device was FDA-approved in March this year for use in adults, says the Redwood City, California firm.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.